April 8, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company plans to hold its Annual General Meeting 2020 as scheduled at 5.00 pm on April 20, 2020, but takes precautionary measures.

  • Due to the risk for spread of infection InDex plans to limit the scope of the Annual General Meeting and the presence of the Board of Directors and Management.
  • There will be no presentation by the CEO at the Annual General Meeting. InDex plans to provide update via other channels close to the Annual General Meeting.
  • No food or refreshments will be served.
  • The number of attendees will be limited in accordance with the restrictions in force at the time of the Annual General Meeting.

To ensure the health and safety of our shareholders, employees and other stakeholders, InDex decided on certain precautionary measures related to its Annual General Meeting 2020. InDex is closely monitoring the development around covid-19 and is following recommendations from relevant national authorities, such as The Public Health Agency of Sweden. 

InDex plans to hold its Annual General Meeting 2020 as scheduled at 5:00 pm on April 20, 2020, at Setterwalls Advokabyrå’s premises (address Sturegatan 10, Stockholm), but with a limited scope. Due to the risk for infection, InDex has decided to limit the scope of the meeting and the presence of the Board of Directors and Management will be limited.

Individuals who feel sick or where there is a risk of infection are expected to refrain from participating in person. Please refer to the Public Health Agency of Sweden for updated information regarding covid-19, www.folkhalsomyndigheten.se.

Even though InDex is taking precautions to minimize the risk for exposure to covid-19, the company is unable to guarantee that attendees will not be exposed to the virus. InDex would like to remind shareholders of the possibility of not attending the meeting in person. Instead they can appoint a proxy who will vote on their behalf. Shareholders who want to authorize a proxy to vote on their behalf, can find relevant templates at: https://www.indexpharma.com/en/annual-general-meeting-2020/. Please be aware that voting-rights registration may also be required.


For more information:

Johan Gileus, CFO

E-mail: [email protected]


InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail [email protected] and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com


The information was submitted for publication through the agency of the contact person set out above at 08:00 CET on April 8, 2020.